Compliance Reg 24 A Annual Secretarial Compliance Report
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals Ltd (BSE Scrip Code: 524711) has filed its Annual Secretarial Compliance Report for the financial year ended 31 March 2025, as required under SEBI Regulation 24A. The report was prepared by Practicing Company Secretary Aakanksha Dubey & Co. and signed by Executive Director Dhananjaya Alli. For FY2024-25, the PCS reported NIL new deviations across SEBI regulations such as LODR, Insider Trading, Substantial Acquisition, and Depositories rules. The company complied with Secretarial Standards, policy adoption, document preservation, board performance evaluation, related party transaction approvals, and disclosure timelines. However, the PCS flagged that the company does not currently maintain a functional website. The report also lists several past non-compliances (delayed audited results submission for Q4 FY23, delayed appointment of Company Secretary/Compliance Officer, missing Women Director, improper composition of Audit and Nomination & Remuneration Committees, and delayed listing approval application for a further issue of shares), all of which have been rectified with BSE fines paid. Trading approval for the further share issue remains pending with BSE.
This is a routine annual compliance filing with no new penalties or material adverse findings for the current year, so it is largely neutral for the stock. Shareholders should note, however, the company's lack of a functional website (a basic disclosure norm) and the pending BSE trading approval for a past share issue, which point to weak governance housekeeping.